Table 3.
Results of the mixed models performed on serum anti-Müllerian hormone (AMH).
| Including all available samples* | Treatment level |
Treatment scheme |
||||||
|---|---|---|---|---|---|---|---|---|
| TL1 | TL2 | TL3 | TL2 versus TL3 (P-value) | TL2/3 COPDAC-28 arm | TL2/3 DECOPDAC-21 arm | COPDAC-28 vs DECOPDAC-21 (P-value) | ||
| AMH | ||||||||
| Intercept: T0: at diagnosis | 0.63 (0.19; 2.05) | 0.71 (0.20; 2.57) | 0.82 (0.24; 2.85) | 0.65 (0.20; 2.09) | 0.139 | 0.45(0.12; 1.66) | 0.54 (0.15; 1.94) | 0.504 |
| T1: after 2× OEPA | 0.05 (0.04; 0.07), P < 0.001 | 0.05 (0.03; 0.09), P < 0.001 | 0.04 (0.03; 0.06), P < 0.001 | 0.07 (0.05; 0.10), P < 0.001 | 0.717 | 0.05 (0.04; 0.07), P < 0.001 | 0.05 (0.03; 0.08), P < 0.001 | 0.629 |
| T1b/T2: after 1× COPDAC/2× (DE)COPDAC | 0.25 (0.20; 0.32), P < 0.001 | 0.36 (0.20; 0.65), P = 0.001 | 0.25 (0.17; 0.36), P < 0.001 | 0.21 (0.14; 0.32), P < 0.001 | 0.042 | 0.43 (0.31; 0.59), P < 0.001 | 0.07 (0.05; 0.11), P < 0.001 | <0.001 |
| T3: after 4× (DE)COPDAC | 0.32 (0.22; 0.47), P < 0.001 | — | — | 0.34 (0.22; 0.52), P < 0.001 | NA | 0.67 (0.42; 1.07), P = 0.091 | 0.10 (0.06; 0.18), P < 0.001 | <0.001 |
| T4: 2 years PD | 1.06 (0.78; 1.46), P = 0.699 | 1.35 (0.73; 2.51), P = 0.333 | 1.17 (0.77; 1.79), P = 0.458 | 0.76 (0.46; 1.26), P = 0.283 | 0.003 | 0.95 (0.63; 1.43), P = 0.808 | 0.86 (0.53; 1.41), P = 0.555 | 0.654 |
| T5: 2–5 years PD | 1.22 (0.65; 2.28), P = 0.539 | 1.65 (0.41; 6.67), P = 0.480 | 1.18 (0.57; 2.46), P = 0.648 | 0.76 (0.12; 4.69), P = 0.767 | 0.030 | 1.26 (0.52; 3.03), P = 0.609 | 0.73 (0.30; 1.78), P = 0.493 | 0.994 |
ACOPDAC-28, cyclophosphamide, vincristine, prednisone and dacarbazine; DECOPDAC-21, doxorubicin, etoposide, cyclophosphamide, vincristine, prednisone and dacarbazine; TL, treatment level; yPD, years post diagnosis.
Linear mixed models on log-transformed serum AMH. Analyses were adjusted for age and hormonal co-treatment (either hormonal contraceptives or GnRH-analogues) at time of sampling. Results were retransformed into the original scale and presented as geometric-mean ratio (GMR) with their corresponding 95% confidence interval (95%CI) and p value. Reported GMRs of all treatment-level and treatment scheme subgroups were calculated using the AMH at diagnosis (T0) as intercept in the model. P values represent the estimated differences between subgroups, using the respective T follow-up as intercept in the model.
Samples drawn in patients after receiving pelvic radiotherapy (n = 4 T4 and n = 1 T5 samples) were excluded from the analyses.